



'New Tools for a TB-free World'

Enhancing the British Contribution to the Development and Introduction of New Tuberculosis Drugs, Diagnostics and Vaccines

9.30 am – 5.00 pm Monday 5th June 2006
The Lecture Theatre, Royal Society of Medicine
1 Wimpole Street, London W1G 0AE

Programme

- 9.00 am Arrival and Registration
- 9.30 am **Welcome**
- Prof Peter Davies, Secretary of TB Alert, and Past President of the Respiratory Section, Royal Society of Medicine
- 9.40 am **The Need for New Tools in the Global Campaign to Stop TB**
- Dr Chris Dye, Chief Epidemiologist, Stop TB Department, World Health Organization
- 10.00 am **The Role and Progress of the International Public Private Initiatives (PPIs) in the Development of New TB Drugs, Diagnostics and Vaccines**
- Dr Maria Freire, CEO, Global Alliance for TB Drug Development
- Dr Vinand Nantulya, Senior Policy and Implementation Officer, Foundation for Innovative New Diagnostics (FIND)
- Dr Jerald Sadoff, President and CEO, Aeras Global TB Vaccine Foundation
- 10.45 am Question & Answer

We are grateful to AstraZeneca and GenusPharma for an unrestricted educational grant in support of this conference. We are also grateful for the support of the Global Alliance for TB Drug Development., the Foundation for Innovative New Diagnostics (FIND), and Aeras Global TB Vaccine Foundation.

- 11.15 am Coffee
- 11.30 am **A New Landscape for the Funding of Drug Development for Neglected Diseases**
- Anne-Laure Ropars, Senior Policy Analyst and Head of the London Unit, The George Institute for International Health
- 11.50 am **Current British Research on the Development of TB Drugs, Diagnostics and Vaccines: Progress and Constraints**
Session Chair: Professor Ali Zumla, Director, Centre for Infectious Diseases and International Health, University College London
- Dr Denny Mitchison, Emeritus Professor, and Dr Amina Jindani, Honorary Senior Lecturer, St. George's, University of London
- Dr Helen McShane, Head of Clinical Department Progressing TB Vaccine, University of Oxford
- Dr Ajit Lalvani, Nuffield Department of Clinical Medicine, University of Oxford (From October 2006, Professor of Infectious Disease, Imperial College, University of London)
- With time for questions
- 1.00 pm Lunch
- 2.00 pm **The Current Contribution of UK Pharmaceutical Companies to the Development and Introduction of TB Drugs, Diagnostics and Vaccines: Progress and Constraints**
Session Chair: Paul Thorn, Author of '*Tuberculosis Survival Handbook*'
- Panel of representatives from pharmaceutical companies:
- Peter Ellis, Biotec Laboratories Ltd
- Chris Granger, Oxford Immunotec
- Steve Woods, Sales Manager, UK and Ireland, Cellectis
- Peter Ballard, Genus Pharmaceuticals Ltd
- Ian Boulton, Director of Global Commercial Strategy for Diseases of the Developing World, Glaxo Smith Kline
- 3.00 pm Coffee

3.30 pm **The Role of Public Agencies in Encouraging the Development of New TB Drugs, Diagnostics and Vaccines: Opportunities and Limitations**

Session Chair: Paul Sommerfeld, Chair, TB Alert

Panel of representatives of public agencies:

Anil Vaidya, Sector Specialist Biotechnology and Healthcare, UK Trade & Investment (Joint department of Foreign and Commonwealth Office and of Dept of Trade and Industry)

Billy Stewart, Health Adviser, Policy Division, Department for International Development

Dr Ann Rawkins, Senior Research Scientist, TB Programme Board, Health Protection Agency

Dr Valerie Snewin, International Activities Manager, Wellcome Trust

4.15 pm **Ways Forward**

Debate and Adoption of the *Final Conference Communiqué*

4.45pm **Closing Remarks**

Paul Sommerfeld, Chair, TB Alert and Chair, Stop TB Partnership Working Group on Advocacy, Communication and Social Mobilisation

5.00 pm Close